CDT Equity Inc. reported 13,693,866 shares of common stock outstanding as of Aug. 31, following a recent issuance and the exercise of pre-funded warrants. Based on the stock’s Aug. 31 closing price, the company said its market capitalization was approximately $23.0 million, while stockholders’ equity was approximately $103 million as of June 30. The company also confirmed that it no longer has outstanding deficiencies with Nasdaq. The latest disclosure updates earlier coverage that cited a $1.16 million market capitalization after CDT shares fell 20.95% to $1.17 in after-hours trading, following a regular-session decline of 11.90% to $1.48. Earlier filings covered a 12.13 million-share issuance, Nasdaq status, reverse stock-split authority capped at 1-for-500 and leadership changes. James Bligh became Chief Executive Officer effective Aug. 31 while remaining Chief Financial Officer and a board member until a successor is appointed; former CEO and director Andrew Regan resigned from both roles and is due $50,000 per month for six months under a separation arrangement. CDT describes itself as a data-driven biopharmaceutical development company using artificial intelligence, solid-form chemistry and strategic partnerships to advance therapeutic assets.